Cellebrite DI Ltd. (CLBT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLBT SEC filings page.
Cellebrite DI Ltd. (CLBT) reported $475.7M in revenue for fiscal year 2025, up 18.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is scaling with stable gross economics, while cash generation exceeds reported earnings and expansion absorbs substantial investment.
FY2025 operating cash flow of$173.5M was more than twice net income of$78.3M , showing cash generation was not dependent on reported earnings alone. The same year produced free cash flow of$160.3M after a FY2024 net loss of$283.0M , making the profit line unusually volatile relative to underlying cash generation.
Revenue growth from FY2023 to FY2025 occurred alongside an operating margin near
FY2025 investing cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cellebrite DI Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cellebrite DI Ltd. has an operating margin of 14.0%, meaning the company retains $14 of operating profit per $100 of revenue. This strong profitability earns a score of 68/100, reflecting efficient cost management and pricing power. This is down from 14.2% the prior year.
Cellebrite DI Ltd.'s revenue surged 18.6% year-over-year to $475.7M, reflecting rapid business expansion. This strong growth earns a score of 83/100.
Cellebrite DI Ltd. has a moderate D/E ratio of 0.94. This balance of debt and equity financing earns a leverage score of 48/100.
Cellebrite DI Ltd.'s current ratio of 1.56 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.
Cellebrite DI Ltd. converts 33.7% of revenue into free cash flow ($160.3M). This strong cash generation earns a score of 95/100.
Cellebrite DI Ltd. earns a strong 16.2% return on equity (ROE), meaning it generates $16 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 69/100. This is up from -84.2% the prior year.
Cellebrite DI Ltd. scores 4.53, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.8B) relative to total liabilities ($454.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cellebrite DI Ltd. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Cellebrite DI Ltd. generates $2.22 in operating cash flow ($173.5M OCF vs $78.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Cellebrite DI Ltd. held $124.5M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
CLBT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
CLBT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'2510-Q | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $938.9M+36.0% | $787.4M+41.5% | $690.6M+29.6% | $556.6M+30.7% | $532.9M+32.1% | $425.9M+31.1% | $403.3M+18.7% | $324.8M |
| Current Assets | $575.9M+1.5% | $606.1M+46.1% | $567.6M+34.5% | $414.8M+22.9% | $422.1M+42.6% | $337.4M+44.4% | $295.9M+8.3% | $233.6M |
| Cash & Equivalents | $124.5M-35.1% | $179.2M+67.6% | $191.7M+1.1% | $107.0M-3.2% | $189.5M+116.2% | $110.5M+20.5% | $87.6M-40.0% | $91.7M |
| Short-Term Investments | $151.5M+48.8% | $146.9M+105.1% | $101.8M+163.1% | $71.6M+24.3% | $38.7M-13.3% | $57.6M+77.6% | $44.6M | $32.4M |
| Inventory | $7.6M-14.9% | $9.5M+8.6% | $8.9M-10.1% | $8.8M-18.8% | $9.9M-2.3% | $10.8M+33.3% | $10.2M+56.3% | $8.1M |
| Accounts Receivable | $105.0M+27.5% | $93.1M+74401.6% | $82.4M+6.6% | $125K+11.6% | $77.3M-1.9% | $112K | $78.8M+16.7% | N/A |
| Long-Term Investments | $98.0M+167.6% | $85.7M+41.2% | $36.6M+26.8% | $60.7M+731.2% | $28.9M+30.4% | $7.3M-68.0% | $22.1M | $22.8M |
| Goodwill | $119.6M+316.4% | $28.7M+7.0% | $28.7M+7.0% | $26.8M0.0% | $26.8M0.0% | $26.8M0.0% | $26.8M0.0% | $26.8M |
| Total Liabilities | $454.5M+28.2% | $379.0M-36.5% | $354.5M-28.9% | $596.7M+46.1% | $498.7M+51.4% | $408.3M+35.8% | $329.4M-20.3% | $300.8M |
| Current Liabilities | $369.7M+25.1% | $310.0M+30.7% | $295.5M+16.4% | $237.2M+16.0% | $253.8M+22.2% | $204.5M+18.3% | $207.8M+11.4% | $172.9M |
| Non-Current Liabilities | $84.9M+43.7% | $69.0M-80.8% | $59.0M-75.9% | $359.5M+76.4% | $244.8M+101.3% | $203.8M+59.4% | $121.7M-46.3% | $127.9M |
| Total Equity | $484.3M+44.1% | $408.4M+1117.0% | $336.0M+882.2% | -$40.2M-328.7% | $34.2M-53.7% | $17.6M-27.0% | $73.9M+200.7% | $24.1M |
| Retained Earnings | -$86.5M+47.5% | -$128.0M-657.4% | -$164.9M-239.5% | $23.0M-81.8% | $118.1M-40.7% | $126.3M-24.4% | $199.2M+154.0% | $167.1M |
Not reported in any period shown, so not listed: Long-Term Debt.
CLBT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
CLBT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cellebrite DI Ltd. CLBT | FY2025 | $475.7M | $78.3M | 16.5% | $2.8B | 68/100 |
| BOX, INC. BOX | FY2026 | $1.2B | $115.4M | 9.8% | $5.4B | 56/100 |
| CALIX, INC. CALX | FY2025 | $1.0B | $17.9M | 1.8% | $2.3B | 51/100 |
| Paymentus Holdings, Inc. PAY | FY2025 | $1.2B | $66.9M | 5.6% | $4.0B | 72/100 |
| AvePoint, Inc. AVPT | FY2025 | $419.5M | $34.8M | 8.3% | $3.0B | 61/100 |
| Qualys, Inc. QLYS | FY2025 | $669.1M | $198.3M | 29.6% | $6.3B | 72/100 |
Where Cellebrite DI Ltd. Ranks
Frequently Asked Questions
What is Cellebrite DI Ltd.'s annual revenue?
Cellebrite DI Ltd. (CLBT) reported $475.7M in total revenue for fiscal year 2025. This represents a 18.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cellebrite DI Ltd.'s revenue growing?
Cellebrite DI Ltd. (CLBT) revenue grew by 18.6% year-over-year, from $401.2M to $475.7M in fiscal year 2025.
Is Cellebrite DI Ltd. profitable?
Yes, Cellebrite DI Ltd. (CLBT) reported a net income of $78.3M in fiscal year 2025, with a net profit margin of 16.5%.
What is Cellebrite DI Ltd.'s EBITDA?
Cellebrite DI Ltd. (CLBT) had EBITDA of $78.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cellebrite DI Ltd.'s gross margin?
Cellebrite DI Ltd. (CLBT) had a gross margin of 84.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cellebrite DI Ltd.'s operating margin?
Cellebrite DI Ltd. (CLBT) had an operating margin of 14.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cellebrite DI Ltd.'s net profit margin?
Cellebrite DI Ltd. (CLBT) had a net profit margin of 16.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cellebrite DI Ltd.'s return on equity (ROE)?
Cellebrite DI Ltd. (CLBT) has a return on equity of 16.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cellebrite DI Ltd.'s free cash flow?
Cellebrite DI Ltd. (CLBT) generated $160.3M in free cash flow during fiscal year 2025. This represents a 29.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cellebrite DI Ltd.'s operating cash flow?
Cellebrite DI Ltd. (CLBT) generated $173.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cellebrite DI Ltd.'s total assets?
Cellebrite DI Ltd. (CLBT) had $938.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cellebrite DI Ltd.'s capital expenditures?
Cellebrite DI Ltd. (CLBT) invested $13.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cellebrite DI Ltd. spend on research and development?
Cellebrite DI Ltd. (CLBT) invested $113.9M in research and development during fiscal year 2025.
What is Cellebrite DI Ltd.'s current ratio?
Cellebrite DI Ltd. (CLBT) had a current ratio of 1.56 as of fiscal year 2025, which is generally considered healthy.
What is Cellebrite DI Ltd.'s debt-to-equity ratio?
Cellebrite DI Ltd. (CLBT) had a debt-to-equity ratio of 0.94 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cellebrite DI Ltd.'s return on assets (ROA)?
Cellebrite DI Ltd. (CLBT) had a return on assets of 8.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cellebrite DI Ltd.'s P/E ratio?
Cellebrite DI Ltd. (CLBT) trades at 35.4x earnings, its market capitalization divided by net income of $78.3M net income, FY2025. The market capitalization is $2.8B as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cellebrite DI Ltd.'s price-to-sales ratio?
Cellebrite DI Ltd. (CLBT) trades at 5.8x sales, its market capitalization divided by revenue of $475.7M revenue, FY2025. The market capitalization is $2.8B as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cellebrite DI Ltd.'s Altman Z-Score?
Cellebrite DI Ltd. (CLBT) has an Altman Z-Score of 4.53, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cellebrite DI Ltd.'s Piotroski F-Score?
Cellebrite DI Ltd. (CLBT) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cellebrite DI Ltd.'s earnings high quality?
Cellebrite DI Ltd. (CLBT) has an earnings quality ratio of 2.22x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cellebrite DI Ltd.?
Cellebrite DI Ltd. (CLBT) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.